Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions

Journal of Neuroimmune Pharmacology

Volumn 10, Issue 3, 2015, Pages 402-424

  Dumas, Marc Emmanuel ^a   Davidovic, Laetitia ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Biomarker; CNS disease; Mass spectrometry; Metabonomics metabolomics metabolic profiling; Nuclear magnetic resonance; Systems biology

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ADENOSINE TRIPHOSPHATE; ADRENALIN; DOPAMINE; GLYCINE DEHYDROGENASE (DECARBOXYLATING); INOSITOL TRISPHOSPHATE; LEUKOTRIENE B4; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PROSTAGLANDIN D; PROSTAGLANDIN E; PROSTAGLANDIN F1 ALPHA; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TAURINE; TRICARBOXYLIC ACID; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AUTISM; BIPOLAR DISORDER; BRAIN DYSFUNCTION; CAPILLARY ELECTROPHORESIS; CENTRAL NERVOUS SYSTEM DISEASE; DOWN SYNDROME; FRAGILE X SYNDROME; HUMAN; HUNTINGTON CHOREA; LIPIDOMICS; MAJOR DEPRESSION; MASS SPECTROMETRY; METABOLOMICS; MOTOR NEURON DISEASE; NEURONAL CEROID LIPOFUSCINOSIS; PARKINSON DISEASE; PHENOTYPE; POLYNEUROPATHY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE TRAIT LOCUS; RETT SYNDROME; REVIEW; SCHIZOPHRENIA; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; METABOLISM; METABOLOME; PHYSIOLOGY; PROCEDURES;

ANIMALS; BIOMARKERS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; PHENOTYPE;

EID: 84939564424     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-014-9578-5     Document Type: Review

References (111)

1. Aerts JT, Louis KR, Crandall SR, Govindaiah G, Cox CL, Sweedler JV (2014) Patch clamp electrophysiology and capillary electrophoresis-mass spectrometry metabolomics for single cell characterization. Anal Chem 86:3203–3208. doi:10.1021/ac500168d
2. Bahado-Singh RO et al (2013) Metabolomic analysis for first-trimester Down syndrome prediction. Am J Obstet Gynecol 208(5)371:e1-8. doi:10.1016/j.ajog.2012.12.035
3. Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA (2014) Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab TEM. doi:10.1016/j.tem.2014.07.004
4. Barrett E, Ross RP, O’Toole PW, Fitzgerald GF, Stanton C (2012) gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol 113:411–417. doi:10.1111/j.1365-2672.2012.05344
5. Bechara EG et al (2009) A novel function for fragile X mental retardation protein in translational activation. PLoS Biol 7:e16
6. Beckonert O et al (2010) High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc 5:1019–1032
7. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2:2692–2703. doi:10.1038/nprot.2007.376
8. Bird SS, Sheldon DP, Gathungu RM, Vouros P, Kautz R, Matson WR, Kristal BS (2012) Structural characterization of plasma metabolites detected via LC-electrochemical coulometric array using LC-UV fractionation, MS, and NMR. Anal Chem 84:9889–9898. doi:10.1021/ac302278u
9. Blaise BJ, Giacomotto J, Elena B, Dumas ME, Toulhoat P, Segalat L, Emsley L (2007) Metabotyping of Caenorhabditis elegans reveals latent phenotypes. Proc Natl Acad Sci U S A 104:19808–19812
10. Blankman JL, Long JZ, Trauger SA, Siuzdak G, Cravatt BF (2013) ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. Proc Natl Acad Sci U S A 110:1500–1505. doi:10.1073/pnas.1217121110
11. Blasco H et al (2013) Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. J Proteome Res 12:3746–3754. doi:10.1021/pr400376e
12. Blasco H et al (2014) Untargeted 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease. Neurology 82:1167–1174. doi:10.1212/WNL.0000000000000274
13. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M (2008) Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain 131:389–396. doi:10.1093/brain/awm304
14. Brooks AI, Chattopadhyay S, Mitchison HM, Nussbaum RL, Pearce DA (2003) Functional categorization of gene expression changes in the cerebellum of a Cln3-knockout mouse model for Batten disease. Mol Genet Metab 78:17–30
15. Cai HL et al (2012) Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res 11:4338–4350. doi:10.1021/pr300459d
16. Chan MK, Tsang TM, Harris LW, Guest PC, Holmes E, Bahn S (2011) Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol Psychiatry 16:1189–1202. doi:10.1038/mp.2010.100
17. Chen G et al (2014) Amino acid metabolic dysfunction revealed in the prefrontal cortex of a rat model of depression. Behav Brain Res. doi:10.1016/j.bbr.2014.05.027
18. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, Gonzalez RG (1997) Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 94:6408–6413
19. Clarke G et al (2013) The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry 18:666–673. doi:10.1038/mp.2012.77
20. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK (2009) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 106:14728–14733. doi:10.1073/pnas.0904489106
21. Clayton TA et al (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073–1077
22. Cloarec O et al (2005) Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal Chem 77:517–526. doi:10.1021/ac048803i
23. Collins SM, Surette M, Bercik P (2012) The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 10:735–742. doi:10.1038/nrmicro2876
24. Coppola A et al (2013) Branched-chain amino acids alter neurobehavioral function in rats. Am J Physiol Endocrinol Metab 304:E405–E413. doi:10.1152/ajpendo.00373.2012
25. Crockford DJ et al (2006) Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal Chem 78:363–371. doi:10.1021/ac051444m
26. Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13:701–712. doi:10.1038/nrn3346
27. Czech C et al (2012) Metabolite profiling of Alzheimer’s disease cerebrospinal fluid. PLoS ONE 7:e31501. doi:10.1371/journal.pone.0031501
28. Davidovic L, Navratil V, Bonaccorso CM, Catania MV, Bardoni B, Dumas ME (2011) A metabolomic and systems biology perspective on the brain of the Fragile X syndrome mouse model. Genome Res 21:2190–2202. doi:10.1101/gr.116764.110
29. de Diego-Otero Y, Romero-Zerbo Y, el Bekay R, Decara J, Sanchez L, Rodriguez-de Fonseca F, del Arco-Herrera I (2009) Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology 34:1011–1026
30. Dumas ME (2012) Metabolome 2.0: quantitative genetics and network biology of metabolic phenotypes. Mol BioSyst 8:2494–2502. doi:10.1039/c2mb25167a
31. Dumas ME et al (2007) Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models. Nat Genet 39:666–672
32. Dunn WB et al (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 6:1060–1083. doi:10.1038/nprot.2011.335
33. Emiliani FE, Sedlak TW, Sawa A (2014) Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatr 27:185–190. doi:10.1097/YCO.0000000000000054
34. Emond P et al (2013) GC-MS-based urine metabolic profiling of autism spectrum disorders. Anal Bioanal Chem 405:5291–5300. doi:10.1007/s00216-013-6934-x
35. Farrer LA (1985) Diabetes mellitus in Huntington disease. Clin Genet 27:62–67
36. Fonville JM et al (2010) The evolution of partial least squares models and related chemometric approaches in metabonomics and metabolic phenotyping. J Chemometr 24:636–649
37. Fornito A, Bullmore ET (2014) Reconciling abnormalities of brain network structure and function in schizophrenia. Curr Opin Neurobiol 30C:44–50. doi:10.1016/j.conb.2014.08.006
38. Freeman LC (1977) A set of measures of centrality based on betweenness. Sociometry 40:35–41
39. Frost B, Gotz J, Feany MB (2014) Connecting the dots between tau dysfunction and neurodegeneration. Trends Cell Biol. doi:10.1016/j.tcb.2014.07.005
40. Garrod S et al (1999) High-resolution magic angle spinning 1H NMR spectroscopic studies on intact rat renal cortex and medulla. Magn Reson Med 41:1108–1118
41. Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK (2000) An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett 484:169–174
42. Graham SF, Chevallier OP, Roberts D, Holscher C, Elliott CT, Green BD (2013) Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer’s disease. Anal Chem 85:1803–1811. doi:10.1021/ac303163f
43. Griffin JL, Cemal CK, Pook MA (2004) Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. Physiol Genomics 16:334–340
44. Griffin JL, Muller D, Woograsingh R, Jowatt V, Hindmarsh A, Nicholson JK, Martin JE (2002) Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by bioinformatics. Physiol Genomics 11:195–203. doi:10.1152/physiolgenomics.00100.2002
45. Han X et al (2011) Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6:e21643. doi:10.1371/journal.pone.0021643
46. Holmes E et al (2006) Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 3:e327
47. Hsiao EY et al (2013) Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155:1451–1463. doi:10.1016/j.cell.2013.11.024
48. Huang JT et al (2007) CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2:e756. doi:10.1371/journal.pone.0000756
49. Ibanez C, Simo C, Martin-Alvarez PJ, Kivipelto M, Winblad B, Cedazo-Minguez A, Cifuentes A (2012) Toward a predictive model of Alzheimer’s disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem 84:8532–8540. doi:10.1021/ac301243k
50. Ji Y et al (2012) Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J. doi:10.1038/tpj.2012.32
51. Ji Y et al (2011) Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 89:97–104. doi:10.1038/clpt.2010.250
52. Johansen KK et al (2009) Metabolomic profiling in LRRK2-related Parkinson’s disease. PLoS One 4:e7551. doi:10.1371/journal.pone.0007551
53. Kaddurah-Daouk R et al (2013a) Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry 3:e223. doi:10.1038/tp.2012.142
54. Kaddurah-Daouk R et al (2011a) Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatr 1. doi:10.1038/tp.2011.22
55. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12:934–945. doi:10.1038/sj.mp.4002000
56. Kaddurah-Daouk R et al (2011b) Metabolomic changes in autopsy-confirmed Alzheimer’s disease. Alzheimers Dement 7:309–317. doi:10.1016/j.jalz.2010.06.001
57. Kaddurah-Daouk R et al (2012) Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci Rep 2:667. doi:10.1038/srep00667
58. Kaddurah-Daouk R et al (2013b) Alterations in metabolic pathways and networks in Alzheimer’s disease. Transl Psychiatry 3:e244. doi:10.1038/tp.2013.18
59. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M (2012) KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40:D109–D114. doi:10.1093/nar/gkr988
60. Kanekiyo T, Xu H, Bu G (2014) ApoE and Abeta in Alzheimer’s disease: accidental encounters or partners? Neuron 81:740–754. doi:10.1016/j.neuron.2014.01.045
61. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698–712. doi:10.1038/nrd3505
62. Knuesel I et al (2014) Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol 10:643–660. doi:10.1038/nrneurol.2014.187
63. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR (2007) High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 358:159–174. doi:10.1007/978-1-59745-244-1_10
64. Kumar A, Bala L, Kalita J, Misra UK, Singh RL, Khetrapal CL, Babu GN (2010) Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin Chim Acta 411:563–567. doi:10.1016/j.cca.2010.01.016
65. Lalande J et al (2014) 1H NMR metabolomic signatures in five brain regions of the AbetaPPswe Tg2576 mouse model of Alzheimer’s disease at four ages. J Alzheimers Dis JAD 39:121–143. doi:10.3233/JAD-130023
66. Lan MJ et al (2009) Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 14:269–279
67. Latta CH, Brothers HM, Wilcock DM (2014) Neuroinflammation in Alzheimer's disease; a source of heterogeneity and target for personalized therapy. Neuroscience. doi:10.1016/j.neuroscience.2014.09.061
68. Le Belle JE, Harris NG, Williams SR, Bhakoo KK (2002) A comparison of cell and tissue extraction techniques using high-resolution 1H-NMR spectroscopy. NMR Biomed 15:37–44
69. Lin S et al (2013) Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer’s disease in CRND8 mice. Anal Bioanal Chem 405:5105–5117. doi:10.1007/s00216-013-6825-1
70. Mapstone et al (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20(4):415–8. doi:10.1038/nm.3466
71. McLoughlin GA et al (2009) Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res 8:1943–1952
72. Meyer U (2014) Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 75:307–315. doi:10.1016/j.biopsych.2013.07.011
73. Mientjes EJ et al (2006) The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis 21:549–555. doi:10.1016/j.nbd.2005.08.019
74. Mochel F et al (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2:e647. doi:10.1371/journal.pone.0000647
75. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81:89–131
76. Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough VB, Powell SB, Naviaux RK (2014) Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. Transl Psychiatry. 4:e400. doi:10.1038/tp.2014.33
77. Nicholson JK, Connelly J, Lindon JC, Holmes E (2002) Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev 1:153–161
78. Nicholson JK, Lindon JC, Holmes E (1999) ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica; the fate of foreign compounds in biological systems 29:1181–1189
79. Novarino G et al (2012) Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science 338:394–397. doi:10.1126/science.1224631
80. Oliver SG, Winson MK, Kell DB, Baganz F (1998) Systematic functional analysis of the yeast genome. Trends Biotechnol 16:373–378
81. Oresic M et al (2011) Metabolome in progression to Alzheimer’s disease. Transl Psychiatry 1:e57. doi:10.1038/tp.2011.55
82. Orlacchio A, Bernardi G, Martino S (2010) Stem cells: an overview of the current status of therapies for central and peripheral nervous system diseases. Curr Med Chem 17:595–608
83. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC (2007) A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 22:418–423. doi:10.1002/gps.1690
84. Pawson AJ et al (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42:D1098–D1106. doi:10.1093/nar/gkt1143
85. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin JL (2005) High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem 280:42508–42514
86. Penagarikano O, Mulle JG, Warren ST (2007) The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet 8:109–129
87. Piomelli D, Astarita G, Rapaka R (2007) A neuroscientist’s guide to lipidomics. Nat Rev Neurosci 8:743–754. doi:10.1038/nrn2233
88. Pontoizeau C et al (2011) Broad-ranging natural metabotype variation drives physiological plasticity in healthy control inbred rat strains. J Proteome Res 10:1675–1689. doi:10.1021/pr101000z
89. Prabakaran S et al (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9(684–697):643. doi:10.1038/sj.mp.4001511
90. Ramautar R, Somsen GW, de Jong GJ (2009) CE-MS in metabolomics. Electrophoresis 30:276–291. doi:10.1002/elps.200800512
91. Russell WR, Hoyles L, Flint HJ, Dumas ME (2013) Colonic bacterial metabolites and human health. Curr Opin Microbiol 16:246–254. doi:10.1016/j.mib.2013.07.002
92. Salek RM et al (2010) A metabolomic study of the CRND8 transgenic mouse model of Alzheimer’s disease. Neurochem Int 56:937–947. doi:10.1016/j.neuint.2010.04.001
93. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, Bahn S (2008) High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 7(10):4266–4277. doi:10.1021/pr800188y
94. Seidel K, Siswanto S, Brunt ER, den Dunnen W, Korf HW, Rub U (2012) Brain pathology of spinocerebellar ataxias. Acta Neuropathol 124:1–21. doi:10.1007/s00401-012-1000-x
95. Stumpf MP, Thorne T, de Silva E, Stewart R, An HJ, Lappe M, Wiuf C (2008) Estimating the size of the human interactome. Proc Natl Acad Sci U S A 105:6959–6964. doi:10.1073/pnas.0708078105
96. Suhre K et al (2011a) Human metabolic individuality in biomedical and pharmaceutical research. Nature 477:54–60. doi:10.1038/nature10354
97. Suhre K et al (2011b) A genome-wide association study of metabolic traits in human urine. Nat Genet 43:565–569. doi:10.1038/ng.837
98. Sussulini A, Prando A, Maretto DA, Poppi RJ, Tasic L, Banzato CE, Arruda MA (2009) Metabolic profiling of human blood serum from treated patients with bipolar disorder employing 1H NMR spectroscopy and chemometrics. Anal Chem 81:9755–9763. doi:10.1021/ac901502j
99. Tiziani S, Kang Y, Choi JS, Roberts W, Paternostro G (2011) Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library. Nat Commun 2:545. doi:10.1038/ncomms1562
100. Tsang TM, Griffin JL, Haselden J, Fish C, Holmes E (2005) Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopy. Magn Reson Med 53:1018–1024. doi:10.1002/mrm.20447
101. Tsang TM, Haselden JN, Holmes E (2009) Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington’s disease. Neurochem Res 34:1261–1271. doi:10.1007/s11064-008-9904-5
102. Tsang TM, Woodman B, McLoughlin GA, Griffin JL, Tabrizi SJ, Bates GP, Holmes E (2006) Metabolic characterization of the R6/2 transgenic mouse model of Huntington’s disease by high-resolution MAS 1H NMR spectroscopy. J Proteome Res 5:483–492. doi:10.1021/pr050244o
103. Underwood BR et al (2006) Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain J Neurol 129:877–886. doi:10.1093/brain/awl027
104. Viola A, Saywell V, Villard L, Cozzone PJ, Lutz NW (2007) Metabolic fingerprints of altered brain growth, osmoregulation and neurotransmission in a Rett syndrome model. PLoS ONE 2:e157
105. Weng SM, Bailey ME, Cobb SR (2011) Rett syndrome: from bed to bench. Pediatr Neonatol 52:309–316. doi:10.1016/j.pedneo.2011.08.002
106. Wesseling H, Chan MK, Tsang TM, Ernst A, Peters F, Guest PC, Holmes E, Bahn S (2013) A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology. Neuropsychopharmacol 38(12). doi:10.1038/npp.2013.160
107. Wyss MT, Jolivet R, Buck A, Magistretti PJ, Weber B (2011) In vivo evidence for lactate as a neuronal energy source. J Neurosci Off J Soc Neurosci 31:7477–7485. doi:10.1523/JNEUROSCI. 0415-11.2011
108. Xia J, Wishart DS (2010) MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucleic Acids Res 38(Suppl):W71–W77
109. Yao JK et al (2010a) Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. PLoS ONE 5:e9508. doi:10.1371/journal.pone.0009508
110. Yao JK et al (2010b) Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 15:938–953. doi:10.1038/mp.2009.33
111. Yap IK, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK (2010) Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res 9:2996–3004. doi:10.1021/pr901188e